日前,《财富》世界500强百时美施贵宝(BMS)宣布,公司的三款创新药物已被纳入最新版中国国家医保目录,其中包括用于治疗中重度斑块状银屑病的氘可来昔替尼片以及用于治疗梗阻性肥厚型心肌病的玛伐凯泰胶囊。这两款“同类首创”的创新药都是今年在中国上市的。此外,就在今年10月,BMS的“免疫双子星”O药联合Y药获得中国国家药品监督管理局(NMPA)批准,用于一线治疗MSI-H/dMMR 结直肠癌患者。这是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.